

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



石四藥集團有限公司 SSY Group Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2005)

VOLUNTARY ANNOUNCEMENT UPDATE ON PRODUCT DEVELOPMENT

The board of directors (the “Board”) of SSY Group Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that the Group’s Medical Recombinant Collagen Gynecological Gel and B-type Natriuretic Peptide (BNP) Test Kit (fluorescent immunochromatography) have obtained the medical device registration certificates from the Hebei Provincial Drug Administration of China.

Medical Recombinant Collagen Gynecological Gel is mainly used in preventing pathogens from colonizing the vaginal wall, and B-type Natriuretic Peptide (BNP) Test Kit is mainly used in auxiliary diagnostic risk assessment for heart failure through in-vitro quantitative determination of B-type natriuretic peptide (BNP) content in human plasma and whole blood samples.

This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.

By order of the Board
Chow Hing Yeung
Executive Director and Company Secretary

Hong Kong, 27 February 2026

As at the date of this announcement, the Board comprises Mr. Qu Jiguang, Mr. Su Xuejun, Mr. Meng Guo, Mr. Chow Hing Yeung and Ms. Qu Wanrong as executive Directors, Mr. Liu Wenjun as non-executive Director, and Mr. Wang Yibing, Mr. Chow Kwok Wai and Mr. Jiang Guangce as independent non-executive Directors.